© ACCESS Newswire
07.01.2026
WGRX
LISTED
NASDAQ
Wellgistics Health Provides 2026 Corporate Outlook
News Preview
Integration of prescription drug dispensing optimization aritifical intelligence platform EinsteinRx™ into pharmacy client point-of-sales systems has commencedEinsteinRx integration streamlining effort focuses on reducing onboarding process friction and speeding time to implementation prior to scaling pharmacy marketing effortCompany expects...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
07.01.2026
PTGX
LISTED
NASDAQ
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
News Preview
NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026 in San Francisc...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
BAVA
LISTED
CPH
Bavarian Nordic Launches Planned Share Buy-Back Program
News Preview
COPENHAGEN, Denmark, January 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the first tranche of the share buy-back program announced on December 2, 2025, under which the Company intends to repurchase own shares for up to DKK 500 million during 2026....
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© EQS Newswire
07.01.2026
NWRN
LISTED
SIX
EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
News Preview
Newron Pharmaceuticals S.p.A.: EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
Milan, Italy, and Morristown, NJ, USA, January 7, 2026 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ACCESS Newswire
07.01.2026
AIML
LISTED
CSE
AI/ML Appoints Erik Suokas as Chief Operating Officer to Accelerate Commercial Execution and Operational Scale
News Preview
Appointment Supports AIML's Commercial Execution and Operational Scale as the Company Advances Its AI-Driven Cardiac PlatformLeadership Addition Aligns Revenue, Delivery, and Product Execution as AIML Transitions from Innovation to Scale TORONTO, ON / ACCESS Newswire / January 7, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company&...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
ORNBV
LISTED
HEL
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS7 January 2026 at 08.30 EET ...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
BSLN
LISTED
SIX
Basilea and Prokaryotics enter collaboration to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections
News Preview
Allschwil, Switzerland, January 07, 2026...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
07.01.2026
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference
News Preview
RANCHO CUCAMONGA, CA / ACCESS Newswire / January 7, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14th, 2026, at 2:15 pm PT. For access, visit Amphastar's Pharmaceuticals website at h...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
ADXN
LISTED
SIX
Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia
News Preview
Ad Hoc Announcement Pursuant to Art. 53 LR ...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
PRAX
LISTED
NASDAQ
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
News Preview
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten p...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2026
9926
LISTED
HKSE
Ivonescimab's Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study
News Preview
HONG KONG, Jan. 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update in China for its internally developed, first-in-class PD-1/VEGF bispecific antibody, ivonescimab. The updated label incorporates final analysis data from the AK112-301/HARMONi-A study, wh...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
07.01.2026
PTP
LISTED
XETR
Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension
News Preview
Formal written minutes from the U.S. FDA confirms no major concerns identified for the planned Phase 3 PANDA study of [⁶⁸Ga]Ga-PentixaFor in treatment-resistant hypertension and Primary AldosteronismType B pre-IND meeting provided non-binding guidance on key statistical and methodological aspects, enabling refinement of the Phase 3 study designFeed...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
07.01.2026
CRNX
LISTED
NASDAQ
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
News Preview
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten public offering of 7,620,000 share...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2026
ALC
LISTED
NYSE
Alcon Terminates Agreement to Acquire STAAR Surgical
News Preview
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today terminated its definitive merger agreement with STAAR Surgical Company (NASDAQ: STAA) announced on August 5, 2025.
“Throughout this process we remained disciplined with our views on price and risk. Moving forward, our refractive strategy is un...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
6855
LISTED
HKSE
Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288
News Preview
ROCKVILLE, Md. and SUZHOU, China, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced tha...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2026
68270
LISTED
KSC
Celltrion to present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
INCHEON, South Korea, Jan. 6, 2026 /PRNewswire/ -- Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced that Jin-Seok Seo, Chief Executive Officer and Hyuk-Jae Lee, Senior Executive Vice President at Celltrion, will present at the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco, Calif...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2026
45030
LISTED
XJPX
Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference
News Preview
TOKYO, Jan. 6, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced it will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San Francisco, Calif. As a global leader in life sciences, Astellas will use this premier platform to highlight...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2026
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) and $200 million of common stock in separate public offerings registered under the Securities Act of 1933, as amended. Arrowhead al...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
13
LISTED
HKSE
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
News Preview
— Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease — ...
Themefolio
Profiler
Peergroup
© Newsfile
06.01.2026
VMD
LISTED
NASDAQ
Stonegate Capital Partners Initiates Coverage on Viemed Healthcare, Inc. (VMD)
News Preview
Dallas, Texas--(Newsfile Corp. - January 6, 2026) - Viemed Healthcare, Inc. (NASDAQ: VMD). Stonegate Capital Partners initiates their coverage on Viemed Healthcare, Inc. (NASDAQ: VMD). Viemed Healthcare is the leading U.S. provider of in-home post-acute respiratory care, specializing in non-invasive ventilation ("NIV") for patients with...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
BAX
LISTED
NYSE
Baxter to Present at J.P. Morgan 2026 Healthcare Conference
News Preview
Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026. Andrew Hider, Baxter’s president and chief executive officer, is scheduled to present at 2:15 p.m. Pacific Time.
The live webcast of Baxter’s presentation can be accessed at www.baxter.com and wil...
Themefolio
Profiler
Peergroup
© Newsfile
06.01.2026
VIVI
LISTED
CSE
TempraMed Receives First Commercial Order from Israel Distributor and Completes Initial Shipment Enabling Entry into National Pharmacy Network
News Preview
Initial shipment delivered to distributor warehouse supports expansion into B2B pharmacy distribution alongside direct-to-consumer activitiesVancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
GEHC
LISTED
NASDAQ
GE HealthCare Recommends Shareholders Reject “Mini-Tender” Offer by Potemkin Limited
News Preview
GE HealthCare Technologies Inc. (Nasdaq: GEHC) (“GE HealthCare”) announced today that it received notice on January 5, 2026, of an unsolicited “mini-tender” offer by Potemkin Limited to purchase up to 100,000 shares (or a greater amount as outlined in the offer documentation) of GE HealthCare common stock at a price of $54.20 per share in cash. Po...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
COR
LISTED
NYSE
Cencora Announces Date and Time for First Quarter Fiscal 2026 Earnings Release
News Preview
Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2026 on Wednesday, February 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 4, 2026.
Participating in the conference cal...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
EXEL
LISTED
NASDAQ
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 5:15 p.m. PT / 8:15 p.m. ET.
To access the webcast link, log onto www.exelixis.com and proceed to the E...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
NUVB
LISTED
NYSE
Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:45 p.m. PT (6...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
STOK
LISTED
NASDAQ
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chie...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
LISTED
CSE
ME Therapeutics Attending JP Morgan Healthcare Conference
News Preview
ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company discovering and developing novel drugs to reprogram the immune response to cancer, is pleased to share that company representatives will attend and participate in one-on-one meetings at the 44th annual JP Morgan Health...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ANIP
LISTED
NASDAQ
ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
PRINCETON, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ANAB
LISTED
NASDAQ
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan 13, 202...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
XRAY
LISTED
NASDAQ
Dentsply Sirona to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
CHARLOTTE, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026, at 3:00 p.m. PT (6:00 p.m. ET). During the presentation, Dan Scavilla, Pre...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ALMS
LISTED
NASDAQ
Alumis Announces Proposed Public Offering of Common Stock
News Preview
Alumis Announces Proposed Public Offering of Common Stock...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
OPK
LISTED
TLV
OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
News Preview
MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 44th Annual J.P. Morgan Healthcare Conference, being held January 12-15, 2026, at the Westin St. Francis Hotel in San Francisco. Management will be hosting one-on-one meetings with investors and will be participat...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ORIC
LISTED
NASDAQ
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 44th Ann...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
GLUE
LISTED
NASDAQ
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
News Preview
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
PRAX
LISTED
NASDAQ
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
News Preview
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced a proposed public offering of its...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ALVO
LISTED
ICE
Transactions of Managers and Closely Associated Persons
News Preview
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 7,007,321 shares in Alvotech by Alvogen Lux Holdings S.a. r.l. at a price of SEK 44.06 per share. The date of the transaction was December 17, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ALVO
LISTED
ICE
Transactions of Managers and Closely Associated Persons
News Preview
Attached is a copy of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of shares in Alvotech by ATP Holdings ehf. The shares were aquired in two transactions, 4,812,257 shares on December 17, 2025 and 2,110,640 shares...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
JAZZ
LISTED
NASDAQ
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit
News Preview
Positive Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the new standard of care, with or without tislelizumab regardless of PD-L1 statusLate-breaking results to be presented at the 2026 ASCO Gastrointestinal Cancers Symp...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ONC
LISTED
NASDAQ
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
News Preview
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ZYME
LISTED
NYSE
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
News Preview
VANCOUVER, British Columbia, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial evaluati...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
COO
LISTED
NASDAQ
CooperVision bringt weiche MyDay® MiSight® 1 day Kontaktlinsen zur Myopie-Kontrolle auf den Markt
News Preview
Neue Linsen kombinieren fortschrittliches Silikonhydrogelmaterial mit bewährter ActivControl®-Technologie*1, um das Fortschreiten der Myopie bei Kindern zu verlangsamen†2,3FAREHAM, England, 6. Januar 2026 /PRNewswire/ -- CooperVision kündigte heute die bevorstehende Markteinführung der Tageslinsen MyDay® MiSight® 1 day im Vereinigten Königreich un...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
376930
LISTED
KOE
Expanding Healthcare Access for Women's Health -- Noul Unveils AI-Automated Cervical Cancer Diagnostics Solution at CES 2026
News Preview
Dramatically cuts diagnostic workflows by 80%…delivering results in under 20 minutesDecentralized, fully automated diagnostic model helps reduce healthcare infrastructure gaps and supports WHO's 2030 cervical cancer screening goalsEco-friendly, sustainable AI diagnostics with NGSI solid-staining—no methanol, minimal reagents, near-zero wastewater,...
Themefolio
Profiler
Peergroup
© ActuNews
06.01.2026
BLC
LISTED
EURONEXT
BASTIDE : 2026.01.06 - BCM - bilan S2 contrat liquidité 2025
News Preview
BASTIDE LE CONFORT MEDICAL
Société anonyme au capital de 3.360.847,05 €
Siège social : 12 Avenue de la Dame - 30132 CAISSARGUES
305 635 039 RCS NIMES
Bilan du second semestre civil du contrat de liquidité
contracté avec la Société de Bourse Gilbert Dupont
Titre concerné...
Themefolio
Profiler
Peergroup
© ActuNews
06.01.2026
BLC
LISTED
EURONEXT
BASTIDE : 2026.01.06 BLCM - Actions et droits de vote au 31.12.2025
News Preview
BASTIDE LE CONFORT MEDICAL
Société anonyme au capital de 3.360.847,05 €
Siège social : 12, avenue de la Dame - 30132 CAISSARGUES
305 635 039 RCS NIMES
NOMBRE D'ACTIONS ET DE DROITS DE VOTE
(Article L.233-8 II du Code de Commerce et les articles 221-1 et 223-16 du Règlement Génér...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
GNFT
LISTED
EURONEXT
GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 6, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that G1090N – a small molecule and the Company’s lead investigational drug candidate for Ac...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
IPN
LISTED
EURONEXT
Ipsen – Half year statement – 2025 12 31
News Preview
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ACHC
LISTED
NASDAQ
Acadia Healthcare to Participate in 44th Annual J.P. Morgan Healthcare Conference
News Preview
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference, January 12-15, 2026, in San Francisco, California.
In connection with the conference, there will be an online webcast of the Company’s presentation available on the Company’s website starting at 5...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
DGX
LISTED
NYSE
Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium
News Preview
SECAUCUS, N.J., Jan. 6, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that data will be shared on circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing during two poster presentations at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January 8...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
TBRG
LISTED
NASDAQ
TruBridge and The Health Management Academy Launch the Rural Health Collaborative
News Preview
TruBridge, Inc. (NASDAQ: TBRG), a leading provider of healthcare technology solutions for rural and community hospitals, and The Health Management Academy (THMA), a leading executive membership and peer-learning organization, today announced the launch of the Rural Health Collaborative, a new initiative designed to support, modernize, and strength...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
STAA
LISTED
NASDAQ
Broadwood Partners Comments on STAAR Surgical Shareholders’ Rejection of the Company’s Proposed Sale to Alcon
News Preview
Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which together own 30.2% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), commented on the results of the Special Meeting of Shareholders (the “Special Meeting”) that was held earlier today in connection with the proposed acquisit...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ERF
LISTED
EURONEXT
Eurofins Scientific SE: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF T...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
ILMN
LISTED
NASDAQ
Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis
News Preview
Integrated software, AI-driven analytics, and frictionless workflows enable customers to harness the full power of biological insightsSAN DIEGO, Jan. 6, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the release of Illumina Connected Multiomics, a powerful cloud-based research software platform to analyze and visualize multiom...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
AMGN
LISTED
NASDAQ
AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE
News Preview
Acquisition Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid LeukemiaTHOUSAND OAKS, Calif., Jan. 6, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small molecule-targete...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
140410
LISTED
KOE
Mezzion Pharmaceuticals Appoints Physician-Scientist Ridwan Shabsigh, MD, FACS as President & Chief Operating Officer
News Preview
FORT LEE, N.J., Jan. 6, 2026 /PRNewswire/ -- Mezzion Pharmaceuticals, Inc. (Mezzion), a late-stage rare disease biopharmaceutical company developing the first potential treatment for people born with single ventricle congenital heart disease (SV-CHD) living with Fontan circulation, today announced the appointment of Ridwan Shabsigh, MD, FACS to th...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
BLLN
LISTED
NASDAQ
BillionToOne Announces Selection of Northstar Select® as the new liquid biopsy test for LC-SCRUM-TRY clinical study at National Cancer Center Hospital East
News Preview
Ultra-sensitive liquid biopsy is expanding precision medicine access for patients in Japan with treatment-resistant non-small cell lung cancer (NSCLC)MENLO PARK, Calif., Jan. 6, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are acces...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
AUTL
LISTED
NASDAQ
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform
News Preview
Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Autolus will assess the feasibility of Cellares’ Cell Shuttle pla...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
CVS
LISTED
NYSE
CVS Health declares quarterly dividend
News Preview
WOONSOCKET, R.I., Jan. 6, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on February 2, 2026, to holders of record on January 22, 2026....
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
STAA
LISTED
NASDAQ
STAAR Surgical Announces Preliminary Results of Special Meeting of Stockholders
News Preview
STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, announced that based on preliminary estimates by STAAR’s proxy solicitor, STAAR did not receive the necessary stockholder votes to approve the merger agreement with Alcon at the Spe...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
BIO
LISTED
NYSE
Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
News Preview
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz, Chief Operating Officer Jon DiVincenzo, and Chief Financial Officer Roop K. Lakkaraju will host one-on-one meetings with analysts and investors dur...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
